Show simple item record

dc.contributor.authorFitzpatrick, John M
dc.contributor.authorBellmunt, Joaquim
dc.contributor.authorDreicer, Robert
dc.contributor.authorFleshner, Neil E
dc.contributor.authorLogothetis, Christopher J
dc.contributor.authorMoul, Judd W
dc.contributor.authorTombal, Bertrand
dc.contributor.authorZlotta, Alexandre
dc.date.accessioned2011-06-03T10:02:28Z
dc.date.available2011-06-03T10:02:28Z
dc.date.issued2011-04
dc.identifier.citationMaximizing outcomes in genitourinary cancers across the treatment continuum. 2011, 107 Suppl 2:1-12 BJU Int.en
dc.identifier.issn1464-410X
dc.identifier.pmid21382149
dc.identifier.doi10.1111/j.1464-410X.2010.10035.x
dc.identifier.urihttp://hdl.handle.net/10147/132533
dc.description.abstractKey controversies concerning the management of genitourinary cancers across the treatment continua were discussed at the second annual Interactive Genitourinary Cancer Conference (IGUCC) held in February 2010 in Athens, Greece. Prostate cancer is the most common form of cancer among western men and prevention strategies are needed. Trials evaluating 5α-reductase inhibitors have reported beneficial and clinically meaningful results, but uptake remains low for primary prostate cancer prevention. Prostate cancer detection programmes are also important as curative treatments for advanced disease are unavailable. Two large landmark randomized controlled trials reported conflicting results concerning screening efficacy and uncovered high levels of over-diagnosis and potential over-treatment. Tailored management strategies after diagnosis are important and predictive markers that distinguish between aggressive and indolent tumours are needed. The majority of newly diagnosed cases of prostate cancer are clinically localized. Active surveillance of favourable risk patients may be beneficial in the intermediate term, while an integrated approach of multi-modality therapy in patients with adverse features is recommended. The benefits of new technologies such as high-intensity focused ultrasound (HIFU) and robotic prostatectomy have not been established in prospective randomized trials vs current standards of care. A multidisciplinary approach is essential to evolving the management of advanced prostate cancer into a chronic disease paradigm. Docetaxel plus prednisone is the standard first-line chemotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC), but the optimal timing of chemotherapy initiation has not been addressed in randomized clinical trials. Retrospective analyses suggest that asymptomatic patients with adverse prognostic factors for survival may also benefit from receiving chemotherapy. Bladder cancer is a common malignancy and the most expensive cancer per patient. Non-muscle-invasive bladder cancer is a heterogenous disease that requires dynamic multidisciplinary management. Aggressive early intervention may be beneficial in some cases. Platinum-based therapies represent the first-line standard of care for advanced bladder cancer, but the maximum benefit may have been reached for conventional chemotherapies and new strategies are needed. Several ongoing clinical trials are assessing combination chemotherapy and targeted therapy.
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21382149en
dc.subject.meshAged
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshCombined Modality Therapy
dc.subject.meshCystectomy
dc.subject.meshFemale
dc.subject.meshHigh-Intensity Focused Ultrasound Ablation
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshProstatectomy
dc.subject.meshProstatic Neoplasms
dc.subject.meshRandomized Controlled Trials as Topic
dc.subject.meshTreatment Outcome
dc.subject.meshUrinary Bladder Neoplasms
dc.subject.meshWatchful Waiting
dc.titleMaximizing outcomes in genitourinary cancers across the treatment continuum.en
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, Mater Misericordiae Hospital and University College Dublin, Dublin, Ireland.en
dc.identifier.journalBJU internationalen
dc.description.provinceLeinster
html.description.abstractKey controversies concerning the management of genitourinary cancers across the treatment continua were discussed at the second annual Interactive Genitourinary Cancer Conference (IGUCC) held in February 2010 in Athens, Greece. Prostate cancer is the most common form of cancer among western men and prevention strategies are needed. Trials evaluating 5α-reductase inhibitors have reported beneficial and clinically meaningful results, but uptake remains low for primary prostate cancer prevention. Prostate cancer detection programmes are also important as curative treatments for advanced disease are unavailable. Two large landmark randomized controlled trials reported conflicting results concerning screening efficacy and uncovered high levels of over-diagnosis and potential over-treatment. Tailored management strategies after diagnosis are important and predictive markers that distinguish between aggressive and indolent tumours are needed. The majority of newly diagnosed cases of prostate cancer are clinically localized. Active surveillance of favourable risk patients may be beneficial in the intermediate term, while an integrated approach of multi-modality therapy in patients with adverse features is recommended. The benefits of new technologies such as high-intensity focused ultrasound (HIFU) and robotic prostatectomy have not been established in prospective randomized trials vs current standards of care. A multidisciplinary approach is essential to evolving the management of advanced prostate cancer into a chronic disease paradigm. Docetaxel plus prednisone is the standard first-line chemotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC), but the optimal timing of chemotherapy initiation has not been addressed in randomized clinical trials. Retrospective analyses suggest that asymptomatic patients with adverse prognostic factors for survival may also benefit from receiving chemotherapy. Bladder cancer is a common malignancy and the most expensive cancer per patient. Non-muscle-invasive bladder cancer is a heterogenous disease that requires dynamic multidisciplinary management. Aggressive early intervention may be beneficial in some cases. Platinum-based therapies represent the first-line standard of care for advanced bladder cancer, but the maximum benefit may have been reached for conventional chemotherapies and new strategies are needed. Several ongoing clinical trials are assessing combination chemotherapy and targeted therapy.


Files in this item

Thumbnail
Name:
21382149.txt
Size:
2.896Kb
Format:
Text file

This item appears in the following Collection(s)

Show simple item record